A citation-based method for searching scientific literature

Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani, Jacoline E C Bromberg, Peter Hau, René O Mirimanoff, J Gregory Cairncross, Robert C Janzer, Roger Stupp. N Engl J Med 2005
Times Cited: 4142







List of co-cited articles
586 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
44

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
40

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
19

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
18

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
14

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
908
12

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
12

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
12

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
M Esteller, J Garcia-Foncillas, E Andion, S N Goodman, O F Hidalgo, V Vanaclocha, S B Baylin, J G Herman. N Engl J Med 2000
11

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
872
10

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
M Lacroix, D Abi-Said, D R Fourney, Z L Gokaslan, W Shi, F DeMonte, F F Lang, I E McCutcheon, S J Hassenbusch, E Holland,[...]. J Neurosurg 2001
10

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
9

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Monika E Hegi, Annie-Claire Diserens, Sophie Godard, Pierre-Yves Dietrich, Luca Regli, Sandrine Ostermann, Philippe Otten, Guy Van Melle, Nicolas de Tribolet, Roger Stupp. Clin Cancer Res 2004
560
9

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
524
8

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Quinn T Ostrom, Haley Gittleman, Gabrielle Truitt, Alexander Boscia, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2018
694
8

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
Anoop P Patel, Itay Tirosh, John J Trombetta, Alex K Shalek, Shawn M Gillespie, Hiroaki Wakimoto, Daniel P Cahill, Brian V Nahed, William T Curry, Robert L Martuza,[...]. Science 2014
8

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer,[...]. Lancet 2019
122
8

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
479
8

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
8


Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi,[...]. Lancet Oncol 2012
657
8

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran,[...]. J Clin Oncol 2013
595
7

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Pierre Bady, Davide Sciuscio, Annie-Claire Diserens, Jocelyne Bloch, Martin J van den Bent, Christine Marosi, Pierre-Yves Dietrich, Michael Weller, Luigi Mariani, Frank L Heppner,[...]. Acta Neuropathol 2012
186
7

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Jörg Felsberg, Niklas Thon, Sabina Eigenbrod, Bettina Hentschel, Michael C Sabel, Manfred Westphal, Gabriele Schackert, Friedrich Wilhelm Kreth, Torsten Pietsch, Markus Löffler,[...]. Int J Cancer 2011
186
7

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Mark R Gilbert, Meihua Wang, Kenneth D Aldape, Roger Stupp, Monika E Hegi, Kurt A Jaeckle, Terri S Armstrong, Jeffrey S Wefel, Minhee Won, Deborah T Blumenthal,[...]. J Clin Oncol 2013
484
7

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
230
7

Primary brain tumours in adults.
Sarah Lapointe, Arie Perry, Nicholas A Butowski. Lancet 2018
262
7

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Maryam Moradi Binabaj, Afsane Bahrami, Soodabeh ShahidSales, Marjan Joodi, Mona Joudi Mashhad, Seyed Mahdi Hassanian, Kazem Anvari, Amir Avan. J Cell Physiol 2018
95
7

Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, J Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Cristina Birzu, Jack E Geduldig, Kristine Pelton,[...]. Nature 2020
83
8

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
6

MGMT testing--the challenges for biomarker-based glioma treatment.
Wolfgang Wick, Michael Weller, Martin van den Bent, Marc Sanson, Markus Weiler, Andreas von Deimling, Christoph Plass, Monika Hegi, Michael Platten, Guido Reifenberger. Nat Rev Neurol 2014
257
6

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel,[...]. Lancet Oncol 2012
644
6

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
6

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
6


CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.
Quinn T Ostrom, Haley Gittleman, Peter Liao, Toni Vecchione-Koval, Yingli Wolinsky, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2017
688
6

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
6

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R Stupp, M Brada, M J van den Bent, J-C Tonn, G Pentheroudakis. Ann Oncol 2014
267
6

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew A Kanner, Santosh Kesari, David M Steinberg, Steven A Toms, Lynne P Taylor, Frank Lieberman, Antonio Silvani, Karen L Fink,[...]. JAMA 2015
542
6

Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Yu Han, Lin-Feng Yan, Xi-Bin Wang, Ying-Zhi Sun, Xin Zhang, Zhi-Cheng Liu, Hai-Yan Nan, Yu-Chuan Hu, Yang Yang, Jin Zhang,[...]. BMC Cancer 2018
32
18

Clonal evolution of glioblastoma under therapy.
Jiguang Wang, Emanuela Cazzato, Erik Ladewig, Veronique Frattini, Daniel I S Rosenbloom, Sakellarios Zairis, Francesco Abate, Zhaoqi Liu, Oliver Elliott, Yong-Jae Shin,[...]. Nat Genet 2016
302
6

DNA methylation-based classification of central nervous system tumours.
David Capper, David T W Jones, Martin Sill, Volker Hovestadt, Daniel Schrimpf, Dominik Sturm, Christian Koelsche, Felix Sahm, Lukas Chavez, David E Reuss,[...]. Nature 2018
655
5

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Deborah S Malley, Rifat A Hamoudi, Sylvia Kocialkowski, Danita M Pearson, Vincent Peter Collins, Koichi Ichimura. Acta Neuropathol 2011
77
6

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.
Quinn T Ostrom, Haley Gittleman, Paul Farah, Annie Ondracek, Yanwen Chen, Yingli Wolinsky, Nancy E Stroup, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2013
901
5

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Walter Stummer, Uwe Pichlmeier, Thomas Meinel, Otmar Dieter Wiestler, Friedhelm Zanella, Hans-Jürgen Reulen. Lancet Oncol 2006
5

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
Monika E Hegi, Lili Liu, James G Herman, Roger Stupp, Wolfgang Wick, Michael Weller, Minesh P Mehta, Mark R Gilbert. J Clin Oncol 2008
546
5

Malignant gliomas in adults.
Patrick Y Wen, Santosh Kesari. N Engl J Med 2008
5

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
149
5

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Erica H Bell, Peixin Zhang, Barbara J Fisher, David R Macdonald, Joseph P McElroy, Glenn J Lesser, Jessica Fleming, Arup R Chakraborty, Ziyan Liu, Aline P Becker,[...]. JAMA Oncol 2018
55
9

Survival in glioblastoma: a review on the impact of treatment modalities.
P D Delgado-López, E M Corrales-García. Clin Transl Oncol 2016
218
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.